Ascelia Pharma AB (publ) (STO:ACE)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.865
+0.265 (7.36%)
May 5, 2025, 12:55 PM CET

Ascelia Pharma AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
17.3330.2129.5630.3228.52
Upgrade
Research & Development
50.881.27118.11107.5764.76
Upgrade
Other Operating Expenses
--0---0.03
Upgrade
Operating Expenses
68.12111.48147.67137.993.26
Upgrade
Operating Income
-68.12-111.48-147.67-137.9-93.26
Upgrade
Interest Expense
-3.71--0.05-0.08-0.01
Upgrade
Interest & Investment Income
0.771.320.640.010.03
Upgrade
Currency Exchange Gain (Loss)
0.540.5513.938.44-7.19
Upgrade
Other Non Operating Income (Expenses)
-9.61--0--
Upgrade
EBT Excluding Unusual Items
-80.12-109.61-133.16-129.52-100.43
Upgrade
Gain (Loss) on Sale of Investments
----0.68
Upgrade
Pretax Income
-80.12-109.61-133.16-129.52-99.75
Upgrade
Income Tax Expense
-0.09-0.32-1.93-3.62-1.05
Upgrade
Net Income
-80.03-109.29-131.22-125.9-98.7
Upgrade
Net Income to Common
-80.03-109.29-131.22-125.9-98.7
Upgrade
Shares Outstanding (Basic)
5434353326
Upgrade
Shares Outstanding (Diluted)
5434353326
Upgrade
Shares Change (YoY)
60.15%-3.10%5.58%25.46%20.52%
Upgrade
EPS (Basic)
-1.48-3.24-3.77-3.82-3.76
Upgrade
EPS (Diluted)
-1.48-3.24-3.77-3.82-3.76
Upgrade
Free Cash Flow
-62.84-126.79-125.26-116.6-85.92
Upgrade
Free Cash Flow Per Share
-1.16-3.76-3.60-3.54-3.27
Upgrade
EBITDA
-68.05-111.4-147.6-137.8-93.16
Upgrade
D&A For EBITDA
0.070.070.070.10.1
Upgrade
EBIT
-68.12-111.48-147.67-137.9-93.26
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.